目錄:MedChemExpress LLC>>信號通路>> Omidenepag isopropyl | MCE
CAS | 1187451-19-9 | 純度 | 98.07% |
---|---|---|---|
分子量 | 520.6 | 分子式 | C??H??N?O?S |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 5 mg |
貨號 | HY-111406 | 應用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務(wù)。
產(chǎn)品活性:Omidenepag isopropyl 是選擇性的,非前列腺素的 EP2 受體激動劑。Omidenepag isopropyl 在角膜穿透過程中轉(zhuǎn)化為活性產(chǎn)品 Omidenepag,Omidenepag 是高度選擇性的 EP2 受體激動劑。Omidenepag isopropyl 對 EP1,EP2 和 FP 受體有弱親和力。Omidenepag isopropyl 可以降低眼內(nèi)壓 (IOP),有潛力用于青光眼的研究。
研究領(lǐng)域:GPCR/G Protein
作用靶點:Prostaglandin Receptor
In Vivo: Omidenepag isopropyl at 0.0001%, 0.001%, or 0.01%, Xalatan, or vehicle was topically administered to one eye in ocular normotensive monkeys. IOP change after drug administration was compared to the predosing baseline value established on day 1.?Omidenepag isopropyl also shows significant and dose-dependent IOP-lowering effects at doses of 0.0001%, 0.001%, and 0.01% in ocular normotensive monkeys, with mean maximal IOP reductions of 2.4 ± 0.6, 7.6 ± 1.7, and 13.3 ± 1.2 mm Hg at each tested concentration, respectively. The significant decreases in IOP for 0.001% and 0.01% OMDI at time 0 of day 7. Omidenepag isopropyl is hydrolyzed in the eye to Omidenepag (OMD), an EP2 receptor agonist , with a significant ocular hypotensive effect in both ocular normotensive and hypertensive animal models.
In ocular hypertensive monkeys finds that Omidenepag isopropyl lowers IOP by increasing both trabecular outflow facility and uveoscleral outflow.
相關(guān)產(chǎn)品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | GPCR/G Protein Compound Library | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Drug Repurposing Compound Library | FDA Approved & Pharmacopeial Drug Library | Angiogenesis-Related Compound Library | Targeted Diversity Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | CAY10580 | EP3 antagonist 3 | Dinoprost-d4 | TCS 2510 | Vidupiprant | EP2 receptor antagonist-1 | SC 51089 | SC-51322 | Misoprostol acid | Treprostinil sodium | Aganepag isopropyl | Prostaglandin E2 | Taprostene | Cicaprost | Fevipiprant | Carboprost | TG6-10-1 | Latanoprost acid | Carbacyclin | KW-8232 free base | Nocloprost | Cloprostenol isopropyl ester | ICI 192605 | HHS-0701 | Bimatoprost-d5 | AS604872 | KF 13218
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應用于新藥研發(fā)、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業(yè)技術(shù)服務(wù);
• 設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團隊跟蹤最新的制藥及生命科學研究進展,為您提供*新的活性化合物;
• 與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。